tiprankstipranks
Advertisement
Advertisement

NGNE Stock Latest News

Neurogene bolsters cash runway with equity offering
Company AnnouncementsNeurogene bolsters cash runway with equity offering
3h ago
8K
NGNE
Neurogene prices 3.5M shares at $30.00 in public offering
PremiumThe Fly
Neurogene prices 3.5M shares at $30.00 in public offering
1d ago
NGNE
Neurogene 75M Spot Secondary; re-offered at $30.00
PremiumThe Fly
Neurogene 75M Spot Secondary; re-offered at $30.00
2d ago
NGNE
Neurogene announces common stock offering, no amount given
PremiumThe Fly
Neurogene announces common stock offering, no amount given
2d ago
NGNE
Analyst Reiterates Buy on Neurogene as Rett Gene Therapy Data Strengthens Case; $180 Price Target Maintained
PremiumRatings
Analyst Reiterates Buy on Neurogene as Rett Gene Therapy Data Strengthens Case; $180 Price Target Maintained
2d ago
NGNE
Kapoor Reiterates Buy on NGNE, Citing Strong NGN-401 Data and Maintains $70 Price Target
PremiumRatingsKapoor Reiterates Buy on NGNE, Citing Strong NGN-401 Data and Maintains $70 Price Target
2d ago
NGNE
Sami Corwin Reiterates Buy on Neurogene as NGN-401’s Strong Long-Term Rett Data De-Risk Embolden Trial and Support Favorable Risk‑Reward
Premium
Ratings
Sami Corwin Reiterates Buy on Neurogene as NGN-401’s Strong Long-Term Rett Data De-Risk Embolden Trial and Support Favorable Risk‑Reward
3d ago
NGNE
Neurogene reports promising long-term NGN-401 Rett data
Premium
Company Announcements
Neurogene reports promising long-term NGN-401 Rett data
3d ago
8K
NGNE
Neurogene announces data from Phase 1/2 trial of NGN-401
PremiumThe Fly
Neurogene announces data from Phase 1/2 trial of NGN-401
3d ago
NGNE
Neurogene Earns Buy Rating as NGN-401 Shows Superior Efficacy in Rett Syndrome; $60 Price Target Reaffirmed
PremiumRatings
Neurogene Earns Buy Rating as NGN-401 Shows Superior Efficacy in Rett Syndrome; $60 Price Target Reaffirmed
10d ago
NGNE
Neurogene: Buy Rating Reiterated as NGN-401 Rett Program Advances Toward BLA with $70 Price Target Unchanged
PremiumRatings
Neurogene: Buy Rating Reiterated as NGN-401 Rett Program Advances Toward BLA with $70 Price Target Unchanged
23d ago
NGNE
Neurogene: EMBOLDEN Trial Milestone, Competitive Lead Support Reiterated Buy and Unchanged $60 Price Target
PremiumRatings
Neurogene: EMBOLDEN Trial Milestone, Competitive Lead Support Reiterated Buy and Unchanged $60 Price Target
24d ago
NGNE
Neurogene Completes Dosing in Embolden Rett Trial
PremiumCompany AnnouncementsNeurogene Completes Dosing in Embolden Rett Trial
24d ago
8K
NGNE
Neurogene completes dosing in Embolden trial of NGN-401
Premium
The Fly
Neurogene completes dosing in Embolden trial of NGN-401
24d ago
NGNE
Neurogene Stockholders Vote on Directors and Executive Pay
Premium
Company Announcements
Neurogene Stockholders Vote on Directors and Executive Pay
28d ago
8K
NGNE
Neurogene initiated with a Buy at Rodman & Renshaw
PremiumThe Fly
Neurogene initiated with a Buy at Rodman & Renshaw
29d ago
NGNE
Analyst Reiterates Buy on Neurogene, Maintains $70 Price Target on Promising NGN-401 Profile and Solid Cash Runway
PremiumRatings
Analyst Reiterates Buy on Neurogene, Maintains $70 Price Target on Promising NGN-401 Profile and Solid Cash Runway
2M ago
NGNE
Neurogene Maintains Buy Rating as Embolden Trial Progresses and Cash Runway Supports Unchanged $180 Price Target
PremiumRatings
Neurogene Maintains Buy Rating as Embolden Trial Progresses and Cash Runway Supports Unchanged $180 Price Target
2M ago
NGNE
Neurogene reports Q1 EPS ($1.39), consensus ($1.27)
PremiumThe Fly
Neurogene reports Q1 EPS ($1.39), consensus ($1.27)
2M ago
NGNE
Is NGNE a Buy, Before Earnings?
PremiumPre-EarningsIs NGNE a Buy, Before Earnings?
2M ago
NGNE
Neurogene to present on ICV delivery in CNS-targeted gene therapy
Premium
The Fly
Neurogene to present on ICV delivery in CNS-targeted gene therapy
2M ago
NGNE
Neurogene initiated with a Buy at Guggenheim
Premium
The Fly
Neurogene initiated with a Buy at Guggenheim
2M ago
NGNE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >